EXOZYMES INC. Finance Lease, Right-of-Use Asset, Amortization
EXOZYMES INC. (EXOZ) reported Finance Lease, Right-of-Use Asset, Amortization of $25.33 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-08-13
- EXOZYMES INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-06-30 was $11.37K.
- EXOZYMES INC. finance lease, right-of-use asset, amortization for the quarter ending 2026-03-31 was $13.97K.
- EXOZYMES INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $10.55K.
- EXOZYMES INC. finance lease, right-of-use asset, amortization for the quarter ending 2025-09-30 was $10.36K.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 6 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $25.33K 10-Q · filed 2026-08-13 | $35.89K derived: sum of 3 quarters · filed 2026-08-13 | $46.24K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $13.97K 10-Q · filed 2026-05-14 | $24.52K derived: sum of 2 quarters · filed 2026-08-13 | $34.88K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-12-31 | $10.55K derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-13 | $20.91K derived: sum of 2 quarters · filed 2026-08-13 | $27.71K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $10.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $17.16K 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $6.80K 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |